# MMP2
**MMP2** (matrix metallopeptidase 2), also called **gelatinase A** or **72-kDa type IV collagenase**, is a zinc-dependent enzyme of the matrix metalloproteinase (MMP) family that degrades gelatin and several extracellular matrix (ECM) components, including type IV and V collagen, fibronectin, laminin, and elastin.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469639/) • [2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) It was first described and isolated in the 1970s and initially denoted 72-kDa type IV collagenase/gelatinase A, and it is one of the two human gelatinases, the other being MMP-9 (gelatinase B).[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469639/) • [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC3102199/) MMP-2 participates in tissue repair, wound healing, angiogenesis, and embryogenesis, and its dysregulation has been linked to cardiovascular disease, diabetic complications, kidney disease, fibrosis, and cancer.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377)
| Key fact | Detail |
|---|---|
| Family and subgroup | Gelatinase subgroup of the MMP family; gelatinase A, formerly 72-kDa type IV collagenase[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469639/) |
| Principal substrates | Type IV and V collagen, fibronectin, laminin, elastin, gelatin; also native collagen types I, II, and III, though more weakly than the dedicated collagenases[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) • [4](https://pmc.ncbi.nlm.nih.gov/articles/PMC2810947/) |
| Distinctive structure | Three tandem fibronectin type II-like repeats inserted into the catalytic domain, shared with MMP-9, conferring affinity for gelatin[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC2810947/) |
| Activation | Secreted as inactive pro-MMP-2; refractory to serine proteinases and activated at the cell surface by MT1-MMP (MMP-14) with TIMP-2 as a bridging molecule[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792593/) |
| Expression control | Constitutive expression; the gene lacks binding sites for pro-inflammatory transcription factors such as activator protein-1, unlike MMP-9[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC3102199/) |
| Deficiency phenotype | MMP-2-null mice show smaller stature, blunted tumor-related angiogenesis, and abnormal lung alveolarization; hereditary MMP-2 deficiency in Middle Eastern families causes a vanishing bone disorder[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) |
| Disease links | Vascular remodeling, atherosclerosis, aneurysms, diabetic nephropathy and retinopathy, fibrotic scarring, and tumor invasion and metastasis[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) |
## Structure and substrates
MMP-2 belongs to the gelatinases, a subgroup of the MMP family named for their ability to degrade gelatin, the denatured form of collagen.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC3102199/) Like MMP-9, it carries three repeats of a fibronectin type II motif inserted into the catalytic domain, a feature thought to confer affinity for gelatin substrates.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC2810947/) The two gelatinases share similar proteolytic activity against denatured collagens and several ECM molecules, including native type IV, V, and XI collagens, laminin, and aggrecan core protein.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC2810947/)
MMP-2 degrades types IV and V collagens, gelatins, laminin, fibronectin, and elastin.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) It can also digest native collagen types I, II, and III in a manner similar to the collagenases, but its collagenolytic activity in solution is much weaker than that of MMP-1 or other collagenases.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC2810947/) Because pro-MMP-2 is recruited to the cell surface and activated there by membrane-bound MT-MMPs, it can accumulate pericellularly and express meaningful local collagenolytic activity; it may also act as a collaborator, digesting collagenase-clipped collagen fragments that denature at body temperature (37 °C).[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC2810947/) A broader substrate catalog lists collagen types I, III, IV, V, VII, and X, elastin, vitronectin, nidogen, aggrecan, versican, thrombospondin-2, and signaling molecules such as TGF-β LAP/LTBPs, HB-EGF, and MCP-3.[7](https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.70296)
## Activation: a distinctive cell-surface pathway
Most MMPs are secreted as inactive zymogens (pro-enzymes) and activated outside the cell by other MMPs or by serine proteinases that cleave the prodomain.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792593/) MMP-2 is an exception: it is refractory to activation by serine proteinases and is instead activated at the cell surface through a multistep pathway involving membrane-type MMPs (MT-MMPs) and TIMP-2.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792593/)
**The ternary complex.** In the best-understood case, MT1-MMP (MMP-14) first binds TIMP-2 through the inhibitor's N-terminal domain, and the C-terminal domain of the bound TIMP-2 then acts as a receptor for the hemopexin domain of pro-MMP-2.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792593/) An adjacent MT1-MMP molecule that is free of TIMP-2 cleaves the tethered pro-MMP-2 propeptide between Asn37 and Leu38, generating an intermediate that is further processed to the fully active form by intermolecular autocleavage when enough intermediate accumulates at the cell surface.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) None of the other TIMPs can substitute for TIMP-2 in this activation, and MT-MMP-mediated MMP-2 activation is functionally impaired in TIMP-2 knockout mice.[8](https://journals.physiology.org/doi/10.1152/physrev.00048.2003) MT1-MMP is a particularly efficient MMP-2 activator, whereas MT4-MMP and human (but not mouse) MT2-MMP are the only MT-MMPs unable to activate MMP-2.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792593/)
TIMP-2 concentration dictates the outcome rather than simply blocking activity. At low TIMP-2 levels, MT1-MMP cleaves its own direct substrates; at a medium level, most MT1-MMP is bound to TIMP-2 and serves as the pro-MMP-2 receptor, and processing is most efficient, though much of the processed MMP-2 is then inactivated by TIMP-2; at high TIMP-2 levels, all MT1-MMP is inhibited and MMP-2 processing is blocked.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) A TIMP-2-independent route also exists: the tight junction protein claudin can substitute for TIMP-2 and enhance pro-MMP-2 activation by MT-MMPs at tight junctions.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) • [9](https://febs.onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2010.07920.x)
## Regulation
MMP-2 expression is constitutive, and most pro-inflammatory stimuli fail to increase it because the gene, unlike that of MMP-9, lacks binding sites for pro-inflammatory transcription factors such as activator protein-1.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC3102199/) Control therefore rests mainly on zymogen activation and inhibition. The enzyme is regulated by the tissue inhibitors of metalloproteinases (TIMPs), with TIMP-2 playing the prominent role, and by [RECK](https://www.edgepedia.org/reck) (reversion-inducing cysteine-rich protein with Kazal motifs), which acts as an MMP-2 suppressor; MT1-MMP is essential for activating pro-MMP-2 on the cell surface.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) Endogenous inhibitors listed for MMP-2 include TIMP-1, -2, -3, and -4.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC11004056/)
## Physiological roles
MMP-2 contributes to tissue repair, wound healing, angiogenesis, and embryogenesis.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) Mouse genetics indicate it is not indispensable for development: MMP-2-deficient mice are viable, with smaller stature, blunted tumor-related angiogenesis, and abnormal lung alveolarization, a milder phenotype than that of MT1-MMP-null mice, which die within weeks of birth with severe defects in skeletal development and angiogenesis.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) In humans, hereditary MMP-2 deficiency has been described in Middle Eastern families who develop a vanishing bone disorder.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) MMP-2-null mice also show extremely low incidences of cardiac rupture after acute myocardial infarction.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x)
## Disease roles
Dysregulation of MMP-2 is linked to cardiovascular disease, diabetic complications, kidney disease, fibrosis, and cancer.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) In cardiovascular disease it contributes to vascular remodeling, atherosclerosis, and aneurysms; in fibrotic disease it mediates excessive ECM degradation leading to tissue scarring; in diabetes, elevated MMP-2 activity is associated with nephropathy, retinopathy, and cardiovascular complications.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377)
In cancer, MMP-2 facilitates tumor invasion and metastasis by degrading ECM components and promoting angiogenesis.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) Activated MMP-2 is consistently observed in tumor tissues that express MT1-MMP, and MT1-MMP expression and MMP-2 activation levels correlate with tumor invasiveness and malignancy.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) In ovarian cancer models, MMP-2 was shown by small-interfering RNA and neutralizing antibody experiments to play an essential role in tumor growth and metastasis, enhancing peritoneal adhesion of cancer cells through cleavage of fibronectin and vitronectin.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) At the clinical level, diagnostic and prognostic value has been attributed mainly to the gelatinases MMP-2 and MMP-9, whose increased expression and activity have been described in neoplastic, cardiovascular, and respiratory diseases.[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6807355/) Quantitative profiling of substrate cleavage also shows significant selectivity between the substrate repertoires of MMP-2 and MMP-9 despite their similarity.[12](https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1008101)
## Therapeutic targeting
Targeting MMP-2 is difficult because the enzyme has dual functions in tissue remodeling and repair, raising concerns about impaired tissue healing or excessive tissue damage.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) Clinical trials targeting MMP-2 modulation highlight the potential of gelatinase inhibitors, including those directed at MMP-2, to reduce tumor progression in fibrosarcoma, breast, and lung cancers.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) Registered studies include NCT05670834, on the association between Mmp2 gene polymorphism and susceptibility to cataract development, and NCT04773028, on MMP-2 in pulmonary arterial wall remodeling in chronic thromboembolic pulmonary hypertension.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377) Because broad-spectrum synthetic inhibitors targeting MMP active sites suffered harmful side effects in clinical testing, targeting MMP-2 or its activation step has been proposed as a possibly less toxic strategy for suppressing tumor malignancy.[6](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x) Current research directions focus on selective modulators that can balance MMP-2 activity in specific disease environments.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377)
## References
1. [The history of matrix metalloproteinases: milestones, myths, and misperceptions (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469639/)
2. [The Complex Role of Matrix Metalloproteinase-2 (MMP-2) in Health and Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11728377)
3. [Physiology and pathophysiology of matrix metalloproteases (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3102199/)
4. [Progress in matrix metalloproteinase research (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2810947/)
5. [How matrix metalloproteinases regulate cell behavior (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2792593/)
6. [Sato H, Takino T. Coordinate action of MT1-MMP and MMP-2 enhances pericellular proteolysis and invasion. Cancer Science 2010](https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01498.x)
7. [A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer. The FEBS Journal](https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.70296)
8. [Dual Role of Matrix Metalloproteinases in Intimal Thickening and Atherosclerotic Plaque Rupture. Physiological Reviews](https://journals.physiology.org/doi/10.1152/physrev.00048.2003)
9. [Regulation of matrix metalloproteinase activity in health and disease. The FEBS Journal 2011](https://febs.onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2010.07920.x)
10. [Redefining Metalloprotease Specificity through Network Proteolysis (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11004056/)
11. [Reappraisal of Quantitative Gel Zymography for Matrix Metalloproteinases (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6807355/)
12. [Quantitative profiling of protease specificity. PLOS Computational Biology 2021](https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1008101)
---
*Topic: Encyclopedia › Life and health › Biological foundations › Biochemistry and metabolism › Enzyme classes and activities › Proteolytic and peptidase enzymes › Proteases by catalytic mechanism › Metalloproteases › Matrix metalloproteinases (MMP class) › MMP gelatinases (MMP-2, MMP-9)*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 21, 2026; Oct 25, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license